<DOC>
	<DOCNO>NCT00480792</DOCNO>
	<brief_summary>In HIV infect patient , individual expose virus Hepatitis B susceptible develop chronic severe liver disease major risk cirrhosis liver cancer . However , exist protocol vaccination Hepatitis B less efficient HIV-infected patient non HIV-infected-patients , , case response , longevity follow carefully . This study compare efficacy standard protocol vaccination GenHevac-B 2 protocol , double-dose GenHevac-B set intradermal injection Genhevac-B , HIV-infected patient lymphocytes T CD4 level 200 permm3 .</brief_summary>
	<brief_title>Trial Comparing Three Strategies Vaccination Against Virus Hepatitis B HIV Infected Patients</brief_title>
	<detailed_description>Comparison 3 vaccination strategy Hepatitis B patient HIV infection T CD4 200 per mm3 Intervention : 1 . Arm A : GenHevac-B 20 microgramme Intramuscular use M0 , M1 , M6 2 . Arm B : GenHevac-B 40 microgramme Intramuscular use M0 , M1 , M2 , M6 3 . Arm C : GenHevac-B 4 microgramme Intradermal use M0 , M1 , M2 , M6</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age Eligible Study : 18 year NA , Genders Eligible Study : Both Criteria Inclusion criterion : HIV infection T CD4 count cell level 200 per mm3 Serology Hepatitis B negative ( AgHBs , AbHBs AbHBc negative ) unchanged ARV last 3 month patient receive ARV screen visit Undetectable last 6 month ARV patient T CD4 level 350 per mm3 Pregnancy test negative screening inclusion visit Any injection vaccine Hepatitis B medical history Acute cytolysis last 3 month transaminases equal 5 time upper normal range HIVHCV coinfected patient , transaminase equal 2 time upper normal non coinfected patient Any vaccine receive one month inclusion History intolerance component GenHevacB Evolutive opportunistic infection treat month screen visit Severe acute pyretic infection unexplained fever week inclusion Evolutive hemopathy solidorgan cancer Prothrombin factor equal 50 percent and/or platelet equal 50 000 per mm3 Immunosuppressive treatment general corticotherapy ( equal 0,5 mg per kg per day 7 day ) last 6 month screen visit Previous Immunomodulating treatment ( interferon , interleukin2 , etc ) plan next 6 month Splenectomy Decompensated cirrhosis ( Child Pugh B C ) Kidney deficient function ( creatinine clearance 50 ml per mn ) Other immunocompromised condition relate HIV infection ( solidorgan transplantation , chemotherapy last 6 month ) Any participation another clinical trial plan Week 28</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Hepatitis B vaccination</keyword>
	<keyword>GenHevac-B Pasteur</keyword>
	<keyword>HIV Infections</keyword>
</DOC>